ACADIA Pharmaceuticals Inc
ACAD24.080USD
+0.550+2.34%
Market hours （ET）Quotes delayed by 15 min
4.02BMarket Cap
17.58P/E TTM
More Details of ACADIA Pharmaceuticals Inc Company
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Company Info
Ticker SymbolACAD
Company nameACADIA Pharmaceuticals Inc
IPO dateMay 27, 2004
CEOMs. Catherine Owen Adams
Number of employees653
Security typeOrdinary Share
Fiscal year-endMay 27
Address12830 El Camino Real
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92130
Phone18585582871
Websitehttps://acadia.com/
Ticker SymbolACAD
IPO dateMay 27, 2004
CEOMs. Catherine Owen Adams
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Mr. Daniel B. (Dan) Soland
Mr. Daniel B. (Dan) Soland
Independent Director
Independent Director
44.04K
+27.09%
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Executive Vice President and Head of Research and Development
Executive Vice President and Head of Research and Development
--
--
Mr. Mark C. Schneyer
Mr. Mark C. Schneyer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Edmund P. Harrigan
Dr. Edmund P. Harrigan
Independent Director
Independent Director
--
--
Mr. Thomas Andrew (Tom) Garner
Mr. Thomas Andrew (Tom) Garner
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Mr. Daniel B. (Dan) Soland
Mr. Daniel B. (Dan) Soland
Independent Director
Independent Director
44.04K
+27.09%
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q2
FY2023Q1
By BusinessUSD
Name
Revenue
Proportion
NUPLAZID
159.72M
65.37%
DAYBUE
84.60M
34.63%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
NUPLAZID
159.72M
65.37%
DAYBUE
84.60M
34.63%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
25.62%
BlackRock Institutional Trust Company, N.A.
11.22%
The Vanguard Group, Inc.
9.07%
RTW Investments L.P.
5.10%
State Street Global Advisors (US)
4.18%
Other
44.81%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
25.62%
BlackRock Institutional Trust Company, N.A.
11.22%
The Vanguard Group, Inc.
9.07%
RTW Investments L.P.
5.10%
State Street Global Advisors (US)
4.18%
Other
44.81%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.94%
Hedge Fund
36.72%
Investment Advisor/Hedge Fund
23.21%
Research Firm
4.68%
Pension Fund
1.03%
Sovereign Wealth Fund
0.88%
Individual Investor
0.58%
Bank and Trust
0.34%
Private Equity
0.28%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
668
175.40M
104.80%
-13.00M
2025Q1
688
177.74M
106.20%
-7.86M
2024Q4
643
167.35M
100.34%
-11.57M
2024Q3
599
161.17M
97.17%
-22.69M
2024Q2
603
166.04M
100.49%
-20.26M
2024Q1
612
167.37M
101.58%
-15.73M
2023Q4
589
164.89M
100.43%
-16.10M
2023Q3
560
161.37M
98.56%
-19.17M
2023Q2
557
164.35M
101.06%
-15.99M
2023Q1
589
162.49M
100.16%
-17.75M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
42.88M
25.62%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
18.77M
11.22%
+8.64M
+85.36%
Mar 31, 2025
The Vanguard Group, Inc.
15.18M
9.07%
+1.26M
+9.02%
Mar 31, 2025
RTW Investments L.P.
8.54M
5.1%
-165.38K
-1.90%
Mar 31, 2025
State Street Global Advisors (US)
6.99M
4.18%
+2.47M
+54.68%
Mar 31, 2025
Point72 Asset Management, L.P.
4.65M
2.78%
+2.42M
+108.35%
Mar 31, 2025
Morgan Stanley & Co. LLC
4.26M
2.54%
-1.74M
-29.03%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.95M
1.77%
+77.40K
+2.69%
Mar 31, 2025
Fred Alger Management, LLC
2.77M
1.66%
+54.90K
+2.02%
Mar 31, 2025
Palo Alto Investors LP
2.66M
1.59%
-84.67K
-3.08%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Alger Weatherbie Enduring Growth ETF
4.69%
First Trust NYSE Arca Biotechnology Index Fund
4.65%
iShares Neuroscience and Healthcare ETF
4.3%
Invesco Biotechnology & Genome ETF
2.58%
ALPS Medical Breakthroughs ETF
2.44%
Tema Neuroscience and Mental Health ETF
2.36%
Virtus LifeSci Biotech Products ETF
1.91%
Invesco S&P SmallCap Health Care ETF
1.91%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.82%
Invesco Dorsey Wright Healthcare Momentum ETF
1.58%
View more
Alger Weatherbie Enduring Growth ETF
Proportion4.69%
First Trust NYSE Arca Biotechnology Index Fund
Proportion4.65%
iShares Neuroscience and Healthcare ETF
Proportion4.3%
Invesco Biotechnology & Genome ETF
Proportion2.58%
ALPS Medical Breakthroughs ETF
Proportion2.44%
Tema Neuroscience and Mental Health ETF
Proportion2.36%
Virtus LifeSci Biotech Products ETF
Proportion1.91%
Invesco S&P SmallCap Health Care ETF
Proportion1.91%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion1.82%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.58%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
